Roche-Nurix $2.3B Licensing Agreement for Bexobrutideg: BTK Degrader for Blood Cancers – News and Statistics
Jun 8, 2026 Roche Holding has entered into a licensing agreement with Nurix Therapeutics for an experimental blood-cancer…
Browsing Tag